ArticleEndocrinology2012
Genomic characterization of human and rat prolactinomas.
Article in Endocrinology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 29 citations in OpenAlex.
- SHP2 inhibition reduces somatotroph tumor growth in a pre-clinical model.Neuro-oncology · 2025Article
- Article
- Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies.The EPMA journal · 2021Review
- Pituitary Hyperplasia, Hormonal Changes and Prolactinoma Development in Males Exposed to Estrogens-An Insight From Translational Studies.International journal of molecular sciences · 2020Review
- The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas.Frontiers in endocrinology · 2020Review
- Identification of Potential Biomarkers with Diagnostic Value in Pituitary Adenomas Using Prediction Analysis for Microarrays Method.Journal of molecular neuroscience : MN · 2019Article
- Article
- Identification of driver genes and key pathways of prolactinoma predicts the therapeutic effect of genipin.Molecular medicine reports · 2019Article
- SIX2 Mediates Late-Stage Metastasis via Direct Regulation ofCancer research · 2019Article
- Biomarker Discovery for Immunotherapy of Pituitary Adenomas: Enhanced Robustness and Prediction Ability by Modern Computational Tools.International journal of molecular sciences · 2019Article
- Identification of Transcriptional Metabolic Dysregulation in Subtypes of Pituitary Adenoma by Integrated Bioinformatics Analysis.Diabetes, metabolic syndrome and obesity : targets and therapy · 2019Article
- Histone Citrullination Represses MicroRNA Expression, Resulting in Increased Oncogene mRNAs in Somatolactotrope Cells.Molecular and cellular biology · 2018Article
- Human Prolactinoma: A View of Protein-Protein Interaction Pattern.International journal of endocrinology and metabolism · 2018Article
- Article
- Role of tyrosine kinase inhibitors in the treatment of pituitary tumours: from bench to bedside.Current opinion in endocrinology, diabetes, and obesity · 2017Review
- Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members.Gene · 2015Review
- Identification of differentially expressed genes in pituitary adenomas by integrating analysis of microarray data.International journal of endocrinology · 2015Article
- Ept7 influences estrogen action in the pituitary gland and body weight of rats.Mammalian genome : official journal of the International Mammalian Genome Society · 2014Article
- The many faces of C/EBPδ and their relevance for inflammation and cancer.International journal of biological sciences · 2013Review
- The Role ofIn vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
Abstract
Although prolactinomas can be effectively treated with dopamine agonists, about 20% of patients develop dopamine resistance or tumor recurrence after surgery, indicating a need for better understanding of underlying disease mechanisms. Although estrogen-induced rat prolactinomas have been widely used to investigate the development of this tumor, the extent that the model recapitulates features of human prolactinomas is unclear. To prioritize candidate genes and gene sets regulating human and rat prolactinomas, microarray results derived from human prolactinomas and pituitaries of estrogen-treated ACI rats were integrated and analyzed. A total of 4545 differentially expressed pituitary genes were identified in estrogen-treated ACI rats [false discovery rate (FDR) < 0.01]. By comparing pituitary microarray results derived from estrogen-treated Brown Norway rats (a strain not sensitive to estrogen), 4073 genes were shown specific to estrogen-treated ACI rats. Human prolactinomas exhibited 1177 differentially expressed genes (FDR < 0.05). Combining microarray data derived from human prolactinoma and pituitaries of estrogen-treated ACI rat, 145 concordantly expressed genes, including E2F1, Myc, Igf1, and CEBPD, were identified. Gene set enrichment analysis revealed that 278 curated pathways and 59 gene sets of transcription factors were enriched (FDR < 25%) in estrogen-treated ACI rats, suggesting a critical role for Myc, E2F1, CEBPD, and Sp1 in this rat prolactinoma. Similarly increased Myc, E2F1, and Sp1 expression was validated using real-time PCR and Western blot in estrogen-treated Fischer rat pituitary glands. In summary, characterization of individual genes and gene sets in human and in estrogen-induced rat prolactinomas validates the model and provides insights into genomic changes associated with this commonly encountered pituitary tumor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.